{
  "$schema": "folio-library-entry/v1",
  "id": "10665-117378",
  "blocks": [
    {
      "id": "library/10665-117378/blocks/prose-page-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 1",
      "pageStart": 1,
      "pageEnd": 1,
      "target": "../sections/page-001.md",
      "narrative": null,
      "content": "1274 La Revue de Santé de la Méditerranée orientale, Vol. 13, N°6, 2007\n\nÉtude pilote de la thérapie\nantirétrovirale à Djibouti\n\nA.A. Ahmed' et S. Latoundji? Le\ner ie obus AU ball Aélroll 515 1 dl 35\nPATES «at oLs je\nit Li ii AN cest cale Ce M ne 112 cé Le arcs Eu ci he\nge Ja qe sil ec all) de fall doté QUE on dif 8 Lie 5 Eu LL, ah star\nDr ep à bi ce 190 DS y cts 36 ALL Gi ue jouit Cho Os (L/iseus 400\n+ NRTI 2 gif tte Le LOU Eat, .84/118 CDA at it su Lo us cal s cui\n= TA SL ss tolé che ÿs .(/4) PI 1 + NPTI 2 (7/45) NRTI3 d «(/51) NNRTI 1\nah et dut es JM Cet Gé pt LEA & pe jf able dl Ont eo\nés",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Opening page of a 2007 Eastern Mediterranean Health Journal article in French on a pilot antiretroviral therapy study in Djibouti, with an abstract describing a survey of 112 HIV-positive patients and their treatment efficacy. The Arabic abstract on this page was extracted as garbled text, and the footer also contains garbled characters.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-117378/blocks/prose-page-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 2",
      "pageStart": 2,
      "pageEnd": 2,
      "target": "../sections/page-002.md",
      "narrative": null,
      "content": "Eastern Mediterranean Health Journal, Vol. 13, No. 6, 2007\n\nIntroduction\n\nLa République de Djibouti, d’une superficie\nde 23 000 km?, compte 690 000 habitants.\nLa séroprévalence du VIH est de 2,9 % et\nl’on estime à 9100 le nombre de personnes\nvivant avec le VIH dans le pays [7]. La mise\nà disposition du traitement antirétroviral a\ndémarré en mars 2004. Est éligible au trai-\ntement antirétroviral tout patient séropositif\nau stade IV de la classification SIDA de\nl'Organisation mondiale de la Santé (OMS)\nou ayant des CD4 (Lymphocytes T Clus-\nter of Differenciation 4) < 200/mm°. Les\nschémas thérape",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces the Djibouti antiretroviral therapy study, giving the country's HIV prevalence, treatment eligibility criteria and first- and second-line regimens. It sets out the study objectives and begins describing methods, including how virological efficacy was assessed; the footer is garbled text.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-117378/blocks/prose-page-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 3",
      "pageStart": 3,
      "pageEnd": 3,
      "target": "../sections/page-003.md",
      "narrative": null,
      "content": "1276\n\nmois de traitement, on considère qu’il y a\nun échec virologique si la charge virale est\nsupérieure ou égale à 400 copies/mL et un\nsuccès virologique si la charge virale est\ninférieure à 400 copies/mL. On considère\nqu’il y a un succès immunologique si on a\nune augmentation de plus de 20 % du taux\nde CDA initial et un échec si on a moins de\n20 %. Un taux d’hémoglobine < 12 g/dL\ncorrespond à une anémie, des leucocytes\n< 4 G/L correspondent à une leucopénie\net des plaquettes < 150 G/L à une throm-\nbopénie. L’association d’une anémie +\nleucopénie ou thrombopénie + anémie ou\nleucopénie + throm",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines the criteria for virological and immunological success or failure and for blood abnormalities, and describes the laboratory techniques used for CD4 counts, viral load and blood counts. It begins the results with patients' sociodemographic profile; the footer contains garbled text.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-117378/blocks/prose-page-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 4",
      "pageStart": 4,
      "pageEnd": 4,
      "target": "../sections/page-004.md",
      "narrative": null,
      "content": "Eastern Mediterranean Health Journal, Vol. 13, No. 6, 2007 1277\n\nde Balbala (arrondissements 4 & 5) suivent\nleur traitement à l’hôpital général Peltier.\nLes patients sont suivis à l'hôpital général\nPeltier (36 %), le centre Yonis Toussaint\n(27 %), le centre hospitalier des armées\nfrançaises Bouffard (21 %), le centre Paul\nFaure (8 %), les deux centres de santé de\nl’Organisme de Protection Sociale (7 %) et\nle centre communautaire d’Einguela (1 %).\nLes caractéristiques socio-démographiques\nsont présentées au Tableau 1.\n\nLes principales affections opportunis-\ntes présentées à l’initiation du trai",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reports where patients in the Djibouti study were followed up and their main opportunistic infections at treatment start, with a table of sociodemographic characteristics. It gives the share of patients achieving virological success and notes that efficacy did not differ by regimen.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-117378/blocks/prose-page-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 5",
      "pageStart": 5,
      "pageEnd": 5,
      "target": "../sections/page-005.md",
      "narrative": null,
      "content": "1278 La Revue de Santé de la Méditerranée orientale, Vol. 13, N°6, 2007\n\nTableau 2 Description clinique, biologique et\nthérapeutique de la population d’étude\n\nCaractéristiques Initiation\nIK(%)\nMédiane (ElQ) 80 (70-90)\n\nIMC (kg/m?)\n\nMédiane (ElQ)\nAffections opportunistes\n[Nbre (%)]\n\nStade clinique à l'inclusion\n[Nbre (%)]\n\n18,6 (15,9-21,5)\n\n101 (90,2 %)\n\nStade À 8 (7)\nStade B 29 (26)\nStade C 75 (67)\n\nTaux de CD4 (Imm*)\n\nMédiane (EIQ)\nLignes thérapeutiques\n[Nbre (%)]\n\n118 (52-186)\n\n2 INTI + 1INNTI 57 (51)\n3 INTI 50 (45)\n2 INTI + 11P 5 (4)\n\nIK : indice de Karnofsky.\nIMC : indice de masse corporel",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a table of the study population's clinical, biological and treatment characteristics and reports significant clinical improvement, such as gains in Karnofsky index and body mass index and fewer opportunistic infections. It ends with a table listing the antiretroviral combinations prescribed.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-117378/blocks/prose-page-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 6",
      "pageStart": 6,
      "pageEnd": 6,
      "target": "../sections/page-006.md",
      "narrative": null,
      "content": "Eastern Mediterranean Health Journal, Vol. 13, No. 6, 2007 1279\n\nTableau 4 Efficacité immunologique et\nvirologique\n\nNbre (%)\n\nNiveau virologique (copiesimL)\n\nCV = 400 29 (26)\n\nCV < 400 83 (74)\nNiveau immunologique : coefficient\nd’ascension du taux de CD4 initial\n\n> 20 % 80 (71)\n\n<20% 32 (29\n\nCV: charge virale.\n\nLe coefficient de Spearman (r = 0,51 ;\np < 0,0001) montre une forte corrélation\nentre les deux variables. Les lymphocytes\npermettent d'expliquer au début plus de\n50 % de la variance observée des LT CD4.\n\nPour déterminer le seuil de lymphocytes\ntotaux correspondant au taux de CD4 <200/\nm",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives a table of immunological and virological efficacy and reports a strong correlation between total lymphocytes and CD4 counts, testing different lymphocyte thresholds for starting treatment. It identifies predictors of failure and opens the discussion on low treatment coverage in Djibouti.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-117378/blocks/prose-page-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 7",
      "pageStart": 7,
      "pageEnd": 7,
      "target": "../sections/page-007.md",
      "narrative": null,
      "content": "1280 La Revue de Santé de la Méditerranée orientale, Vol. 13, N°6, 2007\n\nTableau 5 Comparaison des paramètres cliniques et biologiques de la population\nd’étude en début du traitement antirétroviral et au moment de l’enquête selon des\n\nséries appariées\n\nParamètres Initiation Enquête\n(n=112) (n=112)\nPlan clinique\nIMC (kg/m?)\nMédiane (ElQ) 18,6 (15,9-21,5)  20,7(18,3-22,6)  0,0001°\nIK (%)\nMédiane (ElQ) 0,8 (0,7-0,9) 1(0,9-1) 0,0001°\nAffections opportunistes [Nbre (%)] 101 (90,2) 31 (28) 0,0001°\nPlan immuno-virologique\nCD4 (cellules/mm ) 0,0001°\nMédiane (ElQ) 118 (52-186) 200 (136-295)\nCV (log,)\nM",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a table comparing clinical, immunological, haematological and biochemical parameters at treatment start and at the time of the survey. The discussion begins comparing the sociodemographic profile with African studies.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-117378/blocks/prose-page-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 8",
      "pageStart": 8,
      "pageEnd": 8,
      "target": "../sections/page-008.md",
      "narrative": null,
      "content": "Eastern Mediterranean Health Journal, Vol. 13, No. 6, 2007\n\n1281\n\n600 -\n°\n400 -\no\no\nco\nG 200- 02 °6fo : : |\n° Le)\ngo\n\"8 800 EUX 5 |\n8 og8o8l6e oê o o\n07 o\n2007 nomme Damme TT …—\nT | | |\n0,0 1,0 2,0 30 3\nLymphocytes totaux\no CD4 “ Valeurs ajustées\n\nFigure 1 Représentation graphique selon un modèle de régression linéaire de la corrélation\nentre les lymphocytes totaux (LT) et les lymphocytes T CD4 à l'initiation du traitement\n\nantirétroviral\n\nrieur à Djibouti classait la tuberculose en tête\ndes affections opportunistes [6]. Les mêmes\nproportions d’affections opportunistes sont\nretrouvées au Gabon",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Shows a regression plot of the correlation between total lymphocytes and CD4 cells at treatment start, with the figure partly extracted as garbled characters. The discussion compares opportunistic infections, HIV-1 predominance and protease inhibitor use with other African countries and explains the clinical improvement seen.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-117378/blocks/prose-page-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 9",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../sections/page-009.md",
      "narrative": null,
      "content": "1282\n\nLa Revue de Santé de la Méditerranée orientale, Vol. 13, N°6, 2007\n\nTableau 6 Analyse multivariée selon un modèle de régression\n\nlogistique permettant d'identifier les facteurs prédictifs du succès\nthérapeutique\nVariables incluses Analyse univariée Analyse multivariée\ndans le modèle OR (IC 95 %) OR (IC 95 %)\nCentre\n\nCHA 1,00\n\nCPF 0,4 (0,1-1,8) 0,4 (0,06-2,4)\n\nCYT 6,4 (1,5-27) 6,1 (1,2-30,3)\n\nHGP 0,9 (0,4-2,7) 1,3 (0,3-4,5)\n\nOops 2,1 (0,4-12,9) 3,5 (0,4-28,4)\nSexe\n\nMasculin 1,00 1\n\nFéminin 0,5 (0,2-1,1) 0,5 (0,2-1,1)\nÂge (ans)\n\n<35 1,6 (0,7-3,4)\n\n> 35 1,00\nChômage\n\nOui 1,00\n\nNon 1,8 (0,6-",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A table from the multivariate logistic regression identifying factors that predict treatment success, including treatment centre, initial Karnofsky index and clinical stage.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-117378/blocks/prose-page-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 10",
      "pageStart": 10,
      "pageEnd": 10,
      "target": "../sections/page-010.md",
      "narrative": null,
      "content": "Eastern Mediterranean Health Journal, Vol. 13, No. 6, 2007\n\net 124 au Sénégal [3]. L'efficacité théra-\npeutique rejoint celle observée au Bénin\n[4], au Sénégal [3], en Europe [72] et aux\nÉtats-Unis d'Amérique [73,14]. Cepen-\ndant, on retrouve une discordance immuno-\nvirologique chez nos patients [72].\n\nLe dosage des lymphocytes totaux n’est\npas spécifique aux LT CD4 puisqu'ils re-\ngroupent, en plus des LT CDA4, les lympho-\ncytes B et les lymphocytes Natural Killer.\nPourtant à l’initiation du traitement, on\nretrouve une corrélation entre les LT CD4\net les lymphocytes totaux aussi bien dans\nnotr",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the discussion, comparing treatment efficacy with other countries and noting immunological-virological discordance. It discusses the limits of total lymphocyte counts as a CD4 substitute, attributes viral rebound mainly to poor adherence, and notes possible information and classification biases.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-117378/blocks/prose-page-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 11",
      "pageStart": 11,
      "pageEnd": 11,
      "target": "../sections/page-011.md",
      "narrative": null,
      "content": "1284\n\nConclusion\n\nCette étude, portant sur la première cohorte\ndjiboutienne mise sous traitement antirétro-\nviral, montre que le traitement antirétroviral\nest faisable et efficace à Djibouti. Avant\nson extension à l’ensemble du territoire, il\nest nécessaire de renforcer les structures\ncentrales et la prise en charge des infections\nopportunistes.\n\nLa Revue de Santé de la Méditerranée orientale, Vol. 13, N°6, 2007\n\nRemerciements\n\nLes auteurs tiennent à remercier le minis-\ntère de la Santé (en particulier le Dr Saleh\nBanoita), le Programme de lutte contre\nle SIDA, le Secrétariat Exécutif, tous le",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Concludes that antiretroviral therapy is feasible and effective in Djibouti but that central structures and care of opportunistic infections should be strengthened before scale-up. Acknowledgements and the start of the reference list follow.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-117378/blocks/prose-page-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 12",
      "pageStart": 12,
      "pageEnd": 12,
      "target": "../sections/page-012.md",
      "narrative": null,
      "content": "Eastern Mediterranean Health Journal, Vol. 13, No. 6, 2007\n\n15.\n\n16.\n\n17.\n\n18.\n\n19.\n\nChêne G et al. Change in CD4+ cell count\nand the risk of opportunistic infection or\ndeath after highly active antiretroviral\ntreatment. A/IDS, 1998, 12(17):2313-20.\n\nBadri M, Wood R. Usefulness of total lym-\nphocyte count in moritoring highly active\nantiretroviral therapy in resource-limited\nsettings. A/IDS, 2003, 17:541-5.\n\nJacobson MA et al. Absolute or total lym-\nphocyte count as a marker for the CD4 T\nlymphocyte criterion for initiating antiretro-\nviral therapy. A/IDS, 2003, 17(6):917-9.\n\nLorenzi P. Impact",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The end of the reference list for the Djibouti antiretroviral therapy article, citing mainly AIDS and JAMA studies on CD4 counts, total lymphocyte counts, drug resistance and adverse effects.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    }
  ]
}
